Contact us

Best-in-class precision ocular ASO therapeutics driven by human genetics

Our Mission

We leverage human genetics and best-in-class antisense oligonucleotide (ASO) technology to deliver life-changing, precision ocular ASO medicines.

Our focus on differentiated ASO technology, powered by Alloy Therapeutics’ Genetic Medicines platform and novel AntiClastic™ ASO format, paves the way for a unique and rapid path to meaningful ocular solutions for patients.

Our Approach

Our next-generation AntiClastic ASO medicines

Icon Precise Design
Precise Design

Uses established building blocks that make clinical and market-validated ASOs.

icon Improved Potency
Improved Potency

Leverages proprietary structures to improve potency and promote the delivery of antisense to target RNA, and optimizes engagement of RNaseH for precise excision.

Icon Better Medicines
Better Medicines

Minimizes off-target interactions with unintended RNA targets , mitigates the inflammatory response—potentially improving the therapeutic index.

Our Approach Image
Our Approach

Treating severe blinding diseases

Aldebaran utilizes ocular disease genetics to identify targets for well-defined patient populations with broad therapeutic potential. We are passionate about finding solutions for:

  • Inherited retinal disease
  • Age-related macular degeneration
  • glaucoma
Our Science

Ocular Disease Genetics

We are advancing a diversified portfolio of precision ocular AntiClastic ASOs for patients with severe blinding diseases. We are using human iPSC and in vivo models to de-risk and accelerate therapeutics to the clinic.

Meet our team
Hundreds of genes and Millions of patients: Common Hundreds of Genes and Thousands of Patients: Rare
Our Team

We have assembled a world-class group of company builders, scientists, and leaders at the forefront of ocular research and development and ASO therapeutics.

Carlos Loya
Carlos Loya, PhD

Founder,  CEO, Board Director

Icon LinkedIn
Sudhir Agrawal
Sudhir Agarwal, PhD

Co-Founder, SAB Member

Icon LinkedIn
Andrew Peterson
Andrew Peterson, PhD

Co-Founder, SAB Member

Icon LinkedIn
Vinod Vathipadiekal
Vinod Vathipadiekal, PhD

Board Director, Alloy Head of Genetic Medicines

Icon LinkedIn
Chris Pacheco
Chris Pacheco, PhD

Board Director

Icon LinkedIn
Eric Anderson
Errik Anderson

CEO, Founder of Alloy Therapeutics

Icon LinkedIn
Our Investors
82VS - The venture studio of Alloy Therapeutics

82VS, the venture studio of Alloy Therapeutics, helps efficiently launch new multi-asset startup companies by leveraging the capabilities of the Alloy ecosystem at large.

Learn more about 82VS
Icon - Let's Make Better

Let’s make better ocular medicines, together.

Contact us
Contact Us